70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age M Piccart, LJ van't Veer, C Poncet, JMNL Cardozo, S Delaloge, JY Pierga, ... The Lancet Oncology 22 (4), 476-488, 2021 | 232 | 2021 |
Rare mutations in XRCC2 increase the risk of breast cancer DJ Park, F Lesueur, T Nguyen-Dumont, M Pertesi, F Odefrey, F Hammet, ... The American Journal of Human Genetics 90 (4), 734-739, 2012 | 221 | 2012 |
Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles FJ Gracia-Aznarez, V Fernandez, G Pita, P Peterlongo, O Dominguez, ... PloS one 8 (2), e55681, 2013 | 133 | 2013 |
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor P Peterlongo, I Catucci, M Colombo, L Caleca, E Mucaki, M Bogliolo, ... Human molecular genetics 24 (18), 5345-5355, 2015 | 105 | 2015 |
Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative P Aftimos, M Oliveira, A Irrthum, D Fumagalli, C Sotiriou, EN Gal-Yam, ... Cancer discovery 11 (11), 2796-2811, 2021 | 92 | 2021 |
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO … M Lambertini, S Martel, C Campbell, S Guillaume, FS Hilbers, U Schuehly, ... Cancer 125 (2), 307-316, 2019 | 67 | 2019 |
MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients F Cardoso, L van’t Veer, C Poncet, J Lopes Cardozo, S Delaloge, ... J Clin Oncol 38 (suppl 15), 506, 2020 | 64 | 2020 |
Rare variants in XRCC2 as breast cancer susceptibility alleles FS Hilbers, JT Wijnen, N Hoogerbrugge, JC Oosterwijk, MJ Collee, ... Journal of medical genetics 49 (10), 618-620, 2012 | 61 | 2012 |
Plasma miRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from the NeoALTTO trial S Di Cosimo, V Appierto, S Pizzamiglio, P Tiberio, MV Iorio, F Hilbers, ... Clinical cancer research 25 (13), 3887-3895, 2019 | 55 | 2019 |
Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1/2 breast cancer families IMM Lakeman, FS Hilbers, M Rodríguez-Girondo, A Lee, MPG Vreeswijk, ... Journal of medical genetics 56 (9), 581-589, 2019 | 46 | 2019 |
COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration COMPLEXO msouthey@ unimelb. edu. au, MC Southey, DJ Park, ... Breast Cancer Research 15, 1-2, 2013 | 43 | 2013 |
The impact of next generation sequencing on the analysis of breast cancer susceptibility: a role for extremely rare genetic variation? FSM Hilbers, MPG Vreeswijk, CJ van Asperen, P Devilee Clinical genetics 84 (5), 407-414, 2013 | 40 | 2013 |
Road map to safe and well-designed de-escalation trials of systemic adjuvant therapy for solid tumors. MJ Piccart, FS Hilbers, JM Bliss, C Caballero, ES Frank, P Renault, ... AMER SOC CLINICAL ONCOLOGY, 2020 | 39 | 2020 |
Early modulation of circulating microRNAs levels in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy S Di Cosimo, V Appierto, S Pizzamiglio, M Silvestri, J Baselga, M Piccart, ... International journal of molecular sciences 21 (4), 1386, 2020 | 39 | 2020 |
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial M Lambertini, C Campbell, RD Gelber, G Viale, A McCullough, F Hilbers, ... Breast cancer research and treatment 177, 103-114, 2019 | 39 | 2019 |
Genetic variants in TGFβ-1 and PAI-1 as possible risk factors for cardiovascular disease after radiotherapy for breast cancer FSM Hilbers, NB Boekel, AJ van den Broek, R van Hien, S Cornelissen, ... Radiotherapy and Oncology 102 (1), 115-121, 2012 | 31 | 2012 |
Exome sequencing of germline DNA from non-BRCA1/2 familial breast cancer cases selected on the basis of aCGH tumor profiling FS Hilbers, CM Meijers, JFJ Laros, M van Galen, N Hoogerbrugge, ... PloS one 8 (1), e55734, 2013 | 30 | 2013 |
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab treatment optimization trial D Eiger, NF Pondé, D Agbor-Tarh, A Moreno-Aspitia, M Piccart, ... British journal of cancer 122 (10), 1453-1460, 2020 | 29 | 2020 |
Clinical utility of MammaPrint testing in invasive lobular carcinoma: results from the MINDACT phase III trial O Metzger, F Cardoso, C Poncet, C Desmedt, S Linn, J Wesseling, ... European Journal of Cancer 138, S5-S6, 2020 | 25 | 2020 |
Breast Cancer Family Registry, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Giles GG, Devilee P, Benitez J, Hopper JL, Tavtigian SV … DJ Park, F Lesueur, T Nguyen-Dumont, M Pertesi, F Odefrey, F Hammet, ... Am J Hum Genet 90 (4), 734-9, 2012 | 23 | 2012 |